Next Science Ltd
Next Science Limited engages in the research, development, and commercialization of technologies that resolve the issues in human health caused by biofilms, incumbent bacteria, fungus, viruses, and infections in North America, Australia, and New Zealand. It offers SURGX, an antimicrobial wound Gel; acne gel; oral rinse; BACTISURE wound lavage; BlastX, an antimicrobial wound gel that provides woun… Read more
Next Science Ltd (NXS) - Net Assets
Latest net assets as of June 2025: AU$-557.03K AUD
Based on the latest financial reports, Next Science Ltd (NXS) has net assets worth AU$-557.03K AUD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$9.46 Million) and total liabilities (AU$10.02 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$-557.03K |
| % of Total Assets | -5.89% |
| Annual Growth Rate | 12.52% |
| 5-Year Change | -81.69% |
| 10-Year Change | N/A |
| Growth Volatility | 193.94 |
Next Science Ltd - Net Assets Trend (2016–2024)
This chart illustrates how Next Science Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Next Science Ltd (2016–2024)
The table below shows the annual net assets of Next Science Ltd from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | AU$3.44 Million | -73.15% |
| 2023-12-31 | AU$12.82 Million | +8.20% |
| 2022-12-31 | AU$11.85 Million | +10.40% |
| 2021-12-31 | AU$10.73 Million | -42.90% |
| 2020-12-31 | AU$18.80 Million | -2.98% |
| 2019-12-31 | AU$19.37 Million | -18.38% |
| 2018-12-31 | AU$23.74 Million | +557.41% |
| 2017-12-31 | AU$3.61 Million | +169.42% |
| 2016-12-31 | AU$1.34 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Next Science Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7944581738.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$133.93 Million | 3890.42% |
| Other Comprehensive Income | AU$-41.39 Million | -1202.25% |
| Total Equity | AU$3.44 Million | 100.00% |
Next Science Ltd Competitors by Market Cap
The table below lists competitors of Next Science Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Grammer AG
XETRA:GMM
|
$12.50 Million |
|
B.V. Delftsch Aardewerkfabriek "De Porceleyne Fles Anno 1653"
AS:PORF
|
$12.51 Million |
|
Hanssak Co., Ltd.
KQ:430690
|
$12.51 Million |
|
Smith Micro Software Inc
NASDAQ:SMSI
|
$12.51 Million |
|
Energous Corporation
NASDAQ:WATT
|
$12.50 Million |
|
OneMedNet Corp.
NASDAQ:ONMD
|
$12.50 Million |
|
Oasis Home Holding Berhad
KLSE:0357
|
$12.49 Million |
|
TURBOMECANICA S.A.
RO:TBM
|
$12.49 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Next Science Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 12,821,056 to 3,442,483, a change of -9,378,573 (-73.1%).
- Net loss of 10,586,018 reduced equity.
- Share repurchases of 2,594 reduced equity.
- Other comprehensive income increased equity by 1,103,868.
- Other factors increased equity by 106,171.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-10.59 Million | -307.51% |
| Share Repurchases | AU$2.59K | -0.08% |
| Other Comprehensive Income | AU$1.10 Million | +32.07% |
| Other Changes | AU$106.17K | +3.08% |
| Total Change | AU$- | -73.15% |
Book Value vs Market Value Analysis
This analysis compares Next Science Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 12.29x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 19.38x to 12.29x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | AU$0.01 | AU$0.15 | x |
| 2017-12-31 | AU$0.02 | AU$0.15 | x |
| 2018-12-31 | AU$0.13 | AU$0.15 | x |
| 2019-12-31 | AU$0.12 | AU$0.15 | x |
| 2020-12-31 | AU$0.10 | AU$0.15 | x |
| 2021-12-31 | AU$0.05 | AU$0.15 | x |
| 2022-12-31 | AU$0.06 | AU$0.15 | x |
| 2023-12-31 | AU$0.05 | AU$0.15 | x |
| 2024-12-31 | AU$0.01 | AU$0.15 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Next Science Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -307.51%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -46.40%
- • Asset Turnover: 2.48x
- • Equity Multiplier: 2.68x
- Recent ROE (-307.51%) is below the historical average (-124.10%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -182.39% | -2856.21% | 0.05x | 1.19x | AU$-2.58 Million |
| 2017 | -1.35% | -10.10% | 0.12x | 1.15x | AU$-409.85K |
| 2018 | -54.63% | -493.14% | 0.10x | 1.10x | AU$-15.34 Million |
| 2019 | -74.97% | -353.42% | 0.18x | 1.17x | AU$-16.46 Million |
| 2020 | -63.37% | -346.18% | 0.15x | 1.25x | AU$-13.79 Million |
| 2021 | -87.11% | -104.49% | 0.65x | 1.27x | AU$-10.42 Million |
| 2022 | -154.40% | -156.21% | 0.64x | 1.55x | AU$-19.48 Million |
| 2023 | -191.19% | -110.52% | 1.24x | 1.40x | AU$-25.79 Million |
| 2024 | -307.51% | -46.40% | 2.48x | 2.68x | AU$-10.93 Million |
Industry Comparison
This section compares Next Science Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $19,254,961
- Average return on equity (ROE) among peers: -149.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Next Science Ltd (NXS) | AU$-557.03K | -182.39% | N/A | $12.50 Million |
| Aft Pharmaceuticals Ltd (AFP) | $28.23 Million | -47.00% | 1.31x | $53.97 Million |
| Althea Group Holdings Ltd (AGH) | $42.70 Million | -35.24% | 0.26x | $6.03 Million |
| BOD Science Ltd (BOD) | $3.47 Million | -155.95% | 0.53x | $1.38 Million |
| BPH Global Ltd (BP8) | $-1.46 Million | 0.00% | 0.00x | $781.31K |
| Cann Group Ltd (CAN) | $-2.77 Million | 0.00% | 0.00x | $2.39 Million |
| ECS Botanics Holdings Ltd (ECS) | $188.48K | -116.04% | 0.13x | $2.73 Million |
| IDT Australia Ltd (IDT) | $25.01 Million | -24.32% | 0.25x | $8.48 Million |
| Invion Ltd (IVX) | $19.58 Million | -11.45% | 0.02x | $2.48 Million |
| Little Green Pharma Ltd (LGP) | $77.26 Million | -10.55% | 0.12x | $14.26 Million |
| Live Verdure Ltd (LV1) | $362.12K | -1094.69% | 2.55x | $28.27 Million |